Skip to main content
OpenTrials
Completed

NCT Number: NCT01605890

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

The HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same sensitivity to antiretroviral treatment (ART) compared to HIV-1. The ART strategies that are appropriate for the HIV-1 infection are not as effective for HIV-2. Classical triple therapy including PI is less effective for HIV-2. Also, the choice of ARTs in a second line treatment is limited. The first line optimal treatment has to be defined by a prospective and randomized evaluation of other strategies. The primary endpoint will be adapted to the specificity of the HIV-2 infection. The 1st step is to define, with a phase II clinical trial, whether a strategy including 2 NRTIs and raltegravir, as an alternative strategy to the classical triple therapy, shows an immunovirological response, at least, as good as the one obtained with the triple therapy. The hypothesis is that the low ART response observed in HIV-2 infection is due to a low virological strength of the ARTs used and that the combination of 2 NRTIs and raltegravir should show a therapeutic success of at least 50% at week 48.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV-2 Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hôpital Bichat-Claude Bernard

Paris, 75018, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥18 years
  • HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,
  • antiretroviral treatment-naive, whatever the duration and indication of prior treatments,
  • indication to treatment, with at least one of the following criteria : type B or C events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4 lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to 100 copies/mL at screening-visit,
  • Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,
  • French residency for at least one year,
  • Written informed consent, signed by the participant and the investigator (at the latest on the screening-visit and prior any study related intervention)
  • Affiliate or beneficiary of a social security system (State Medical Assistance is not a social security scheme).

Exclusion criteria

  • Absence of effective contraception method(women),
  • Pregnancy, breastfeeding or wish for pregnancy during the trial,
  • Curative treatment of a progressive opportunistic infection not compatible with those evaluated in the present study,
  • Malignant or tumorous affection requiring chemotherapy or radiotherapy,
  • Decompensated cirrhosis,
  • Viral hepatitis C with a Metavir score over F2,
  • Hemoglobinemia below 7g/dL, polynuclear neutrophils below 500/mm3, platelets below 50 000/mm3, creatinine clearance below 50 mL/mn, transaminase, alkaline phosphatase or bilirubin over 2.5N,
  • Contraindication to one of the excipients of study treatments,
  • Insuline-dependent diabetes mellitus not well controlled (with glycated haemoglobin (HbA1C) over 7%),
  • Long-term corticosteroid treatment (more than 3 weeks of treatment),
  • Judicial protection, legal guardianship,
  • Participation in other therapeutic trial or comprising an exclusion period ongoing at the time of the screening-visit.

Treatment and study plan

emtricitabine / tenofovir disoproxil fumarate / raltegravir .

Drug

emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.

raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.

Primary outcomes

  1. Percentage of Participants in Therapeutic Success

    Time frame: at Week 48

    The participants will be considered in therapeutic success at Week 48 if they did not present any of the following events:

    • Plasma HIV-2 RNA load over or equal to 100 copies/mL, starting from Week 24 and confirmed within the next 4 weeks,
    • CD4 lymphocytes gain below 100/mm3 at Week 48 compared to the CD4 lymphocytes counts average between Week-4 and Week 0,
    • Raltegravir permanent discontinuation,
    • Death from any cause,
    • New B or C events confirmed by an endpoint review committee

Secondary outcomes

  1. Median Change in CD4 Lymphocytes Count at Week 12

    Time frame: between Week 0 and Week 12

  2. Number of Clinical and Biological Events

    Time frame: from Week 0 to Week 48

  3. Median Change of CD4 Lymphocytes at Week 48

    Time frame: between Week 0 and Week 48

  4. Percentage of Patients With Plasma HIV-2 RNA < 40 Copies/mL

    Time frame: between Week 0 and Week 48

  5. Number of Participants With Clinical Progression

    Time frame: from Week 0 to Week 48

    Clinical progression is defined as the switch:

    • from category A to B, C or death.
    • from category B to C or death.

  6. Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence

    Time frame: from Week 4 to Week 48

  7. Number of Virological Failure Participants With Resistance Mutations

    Time frame: from Week 0 to Week 48

    Virological failure is defined as plasma HIV-2 RNA load over or equal to 100 copies/mL after plasma HIV-2 RNA load below 100copies/mL, confirmed with a retest within the 4 following weeks. The number and type of mutations in the RT and integrase genes compared to week 0 is being reported.

  8. Number of Participants With Treatment Switch or Discontinuation

    Time frame: from Week 0 to Week 48

    Overall (regardless of the molecule)

  9. Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 48

    Time frame: at Week 48

  10. Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire

    Time frame: from Week 0 to Week 48

    The quality of life questionnaire is the Professional Quality of Life (PROQOL) questionnaire, including 4 dimensions:

    Physical health and symptoms, Relationship with others, Mental and cognitive functioning and Treatment impact For each scale, a score ranging from 0 (the worst answer) to 100 (the best answer) is calculated.

  11. Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 24

    Time frame: Week 24

Sponsors and collaborators

Lead sponsor

ANRS, Emerging Infectious Diseases

Other Gov

Collaborators

  • Gilead Sciences
  • Merck Sharp & Dohme LLC

Registry information

Official study title

ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Acronym: VIH-2

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
May 25, 2012
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.